Sean D Donevan

US Patent:

7491835, Feb 17, 2009

Filed:

Sep 21, 2004

Appl. No.:

10/946540

Inventors:

Sean D. Donevan - Dexter MI, US
Augustine Tobi Osuma - Canton MI, US
Andrew J. Thorpe - Whitmore Lake MI, US
David Juergen Wustrow - Ann Arbor MI, US

Assignee:

Pfizer Inc - New York NY

International Classification:

C07C 233/00

US Classification:

554 63

Abstract:

This invention relates to prodrugs of certain amino acids that bind to the alpha-2-delta (α2δ) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.

US Patent:

7553847, Jun 30, 2009

Filed:

Feb 13, 2006

Appl. No.:

11/352286

Inventors:

Cathryn M. Clary - New York NY, US
Jeroen Van Beek - Ridgefield CT, US
Perry S. Eisman - Southamton NY, US
Sean Donevan - Dexter MI, US
Atul Pande - East Lyme CT, US
Richard Kavoussi - Ann Arbor MI, US

Assignee:

Indevus Pharmaceuticals, Inc. - Lexington MA

International Classification:

A61K 31/4745

US Classification:

514300

Abstract:

The present invention provides methods for treating social anxiety disorder, comprising administering 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone or 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-5-hydroxy-2-oxohexyl) -1-isoindolinone or pharmaceutically acceptable salt, or optical isomer therof, and optionally comprising administering another compound for the treatment of social anxiety disorder that is a GABA agonist.

US Patent:

20030022915, Jan 30, 2003

Filed:

Apr 25, 2002

Appl. No.:

10/133471

Inventors:

Cathryn Clary - New York NY, US
Jeroen Van Beek - Ridgefield CT, US
Perry Eisman - Southampton NY, US
Sean Donevan - Dexter MI, US
Atul Pande - East Lyme CT, US
Richard Kavoussi - Ann Arbor MI, US

International Classification:

A61K031/4745

US Classification:

514/300000

Abstract:

The present invention provides methods and kits for treating obsessive-compulsive disorder, acute stress disorder, post traumatic stress disorder, social anxiety disorder, somatization disorder, specific social phobia, premenstrual dysphoric disorder, anxiety associated with a medical condition, adjustment disorder with anxious mood, dysthymia, specific phobia or fibromyalgia using a compound of Formula I or a pharmaceutically acceptable salt, optical isomer or prodrug thereof The present invention also provides compositions comprising a compound of Formula I or a pharmaceutically acceptable salt, optical isomer or prodrug thereof and an additional compound useful to treat the aforementioned conditions.